Review
Oncology
Xavier Roussel, Francine Garnache Ottou, Florian Renosi
Summary: Plasmacytoid dendritic cells (pDC) are the main type I interferon-producing cells in humans and are capable of regulating innate and adaptive immune responses. Tumor infiltration by pDC is well-documented in various cancers and is associated with unfavorable clinical outcomes. While Blastic Plasmacytoid Dendritic Cells Neoplasm (BPDCN) is a well-described aggressive leukemia derived from pDCs, the understanding of tumor infiltration by mature pDCs in Myeloid Neoplasms (MN) is limited. This review aims to provide a comprehensive overview of pDC biology in MN, emphasizing the need for further research into pDC oncogenesis and immune responses for better therapeutic strategies.
Article
Immunology
Seung-Ji Kang, Ki-Jeong Park, Hye-Mi Jin, Young-Nan Cho, Tae Hoon Oh, Seong Eun Kim, Uh Jin Kim, Kyung-Hwa Park, Sook-In Jung, Tae-Ok Kim, Hyo Shin Kim, Young-Goun Jo, Jae Kyun Ju, Seung-Jung Kee, Yong-Wook Park
Summary: This study reveals that circulating pDCs and cDCs are numerically deficient and functionally impaired in scrub typhus patients. Changes in the expression levels of surface phenotypes of pDCs and cDCs may be influenced by pro-inflammatory cytokines.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Chemistry, Medicinal
Bongki Ko, Yongsoo Jang, Seung-hwa Kwak, Hyun You, Jeong-hyun Kim, Jung-Eun Lee, Hee Dong Park, Soo-Kyung Kim, William A. Goddard, Jung Hyun Han, Yong-Chul Kim
Summary: This study aimed to develop new CMKLR1 antagonists by screening a compound library and evaluated their pharmacokinetic properties in a murine model. The optimized compound S-26d showed potent and orally available antagonist activity, and significantly alleviated symptoms in a psoriasis-like mouse model.
JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Review
Immunology
Binhui Zhou, Toby Lawrence, Yinming Liang
Summary: Plasmacytoid dendritic cells (pDCs) are a special subtype of dendritic cells that produce massive amounts of type I interferon (IFN-I) and play a pivotal role in antiviral immunity. However, in many types of cancer, tumor-infiltrating pDCs do not respond to Toll-like receptor (TLR) stimulation, leading to reduced IFN-alpha production and promoting tumor growth.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Andrea Knight, Lucie Rihova, Romana Kralova, Miroslav Penka, Zdenek Adam, Ludek Pour, Martin Piskacek, Roman Hajek
Summary: The study revealed a significant reduction of pDCs in multiple myeloma patients, while pDCs were found to promote proliferation of MM cells and secrete IFN alpha. These results highlight the role of pDCs in MGUS and MM patients and their potential impact on immune function and treatment outcomes.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Antoni Ribas, Theresa Medina, John M. Kirkwood, Yousef Zakharia, Rene Gonzalez, Diwakar Davar, Bartosz Chmielowski, Katie M. Campbell, Riyue Bao, Heather Kelley, Aaron Morris, David Mauro, James E. Wooldridge, Jason J. Luke, George J. Weiner, Arthur M. Krieg, Mohammed M. Milhem
Summary: In patients with advanced melanoma, combining intratumoral TLR9 agonist vidutolimod with pembrolizumab showed promising clinical activity and manageable safety profile, indicating potential to overcome resistance to PD-1 blockade through IFN response induction.
Article
Immunology
Amal Hasan, Ebaa Al-Ozairi, Nosiba Y. M. Hassan, Shamsha Ali, Rasheed Ahmad, Nada Al-Shatti, Salem Alshemmari, Fahd Al-Mulla
Summary: Severe COVID-19 is associated with a lower frequency of pDCs compared to other circulating DCs, and lower expression levels of HLA-DR, CD123, or CD11c on DCs.
JOURNAL OF INFLAMMATION RESEARCH
(2022)
Review
Biochemistry & Molecular Biology
Sabina Sanchez Hernandez, Martin Roelsgaard Jakobsen, Rasmus O. Bak
Summary: Plasmacytoid dendritic cells (pDCs) have multifaceted roles in immune responses, playing a crucial part in antiviral and antitumor immune activities. The therapeutic approach of utilizing pDCs to enhance tumor-specific immune responses has shown promising effects in clinical trials.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Anastasia Prokopi, Christoph H. Tripp, Bart Tummers, Florian Hornsteiner, Sarah Spoeck, Jeremy Chase Crawford, Derek R. Clements, Mirjana Efremova, Katharina Hutter, Lydia Bellmann, Giuseppe Cappellano, Bruno L. Cadilha, Sebastian Kobold, Louis Boon, Daniela Ortner, Zlatko Trajanoski, Suzie Chen, Tanja D. de Gruijl, Juliana Idoyaga, Douglas R. Green, Patrizia Stoitzner
Summary: Immunotherapy with checkpoint inhibitors has shown impressive results in patients with melanoma, but many still do not benefit from this treatment due to factors such as lack of tumor-infiltrating T cells and loss of intratumoral dendritic cells. In a melanoma mouse model, researchers found that tumor progression is characterized by upregulation of checkpoint molecules and gradual loss of dermal conventional DC 2 subset. Monotherapy with checkpoint blockade was not effective, but boosting DC numbers and activation increased tumor immunogenicity, leading to improved T cell function and delayed tumor growth when combined with antibodies against PD-1 and TIM-3. The study highlights the importance of skin DC in cancer immunotherapy and suggests that restoring DC function is key to enhancing tumor immunogenicity and responsiveness to checkpoint blockade therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Biology
Anders Laustsen, Renee M. Van der Sluis, Albert Gris-Oliver, Sabina Sanchez Hernandez, Ena Cemalovic, Hai Q. Tang, Lars Henning Pedersen, Niels Uldbjerg, Martin R. Jakobsen, Rasmus O. Bak
Summary: Researchers have developed a new method for generating pDCs from whole blood, and these cells exhibit the characteristics and functions of pDCs. While TLR7/9 responses significantly decrease when cultured under GMP standards, this can be rescued by adding ascorbic acid.
Review
Oncology
Jinpu Yang, Xia Liu, Yiwen Cheng, Jingchen Zhang, Feng Ji, Zongxin Ling
Summary: Gastric cancer is the fifth most common neoplasm and the third most deadly cancer worldwide. Helicobacter pylori infection is the major cause of gastric carcinogenesis and triggers immune responses in the host. Plasmacytoid dendritic cells (pDCs), as important components of the tumor immune microenvironment, have been gaining attention for their potential roles in immunosuppression. Recent studies have shown that pDCs play vital roles in the development of immunosuppression in gastric cancer. Understanding the contribution of pDCs to the development and progression of gastric cancer may lead to improved cancer therapy strategies.
FRONTIERS IN ONCOLOGY
(2022)
Review
Medicine, Research & Experimental
Alexey Rzhevskiy, Alina Kapitannikova, Polina Malinina, Arthur Volovetsky, Hamidreza Aboulkheyr Es, Arutha Kulasinghe, Jean Paul Thiery, Anna Maslennikova, Andrei V. Zvyagin, Majid Ebrahimi Warkiani
Summary: Immunotherapy, particularly immune checkpoint inhibitor therapy, has revolutionized cancer treatment in recent years. However, slow uptake in clinical oncology is attributed to high treatment costs, associated toxicities, and variability in patient response. Personalized approaches based on predictive biomarkers have emerged as new tools to enhance the effectiveness of immunotherapy.
Review
Cell Biology
Chunmei Fu, Li Zhou, Qing-Sheng Mi, Aimin Jiang
Summary: Although clinical trials of dendritic cell-based vaccines have been disappointing, recent studies have shown that cross-priming mediated by dendritic cells plays a critical role in generating anti-tumor immunity. This supports further development of dendritic cell vaccines as immunotherapy. Recent clinical studies have also shown promise with naturally circulating dendritic cells and dendritic cell-derived exosomes as cancer vaccines.
Article
Biochemistry & Molecular Biology
Giulio Verna, Marina Liso, Elisabetta Cavalcanti, Giusy Bianco, Veronica Di Sarno, Angelo Santino, Pietro Campiglia, Marcello Chieppa
Summary: Dendritic cells can be divided into myeloid dendritic cells and plasmacytoid dendritic cells, which play important roles in regulating immune responses. Inflammatory bowel diseases are characterized by leaky intestinal barrier and translocation of bacterial lipopolysaccharide. It was found that quercetin can modulate dendritic cell responses through a specific molecular pathway.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Michael S. Parappilly, Yuki Chin, Riley M. Whalen, Ashley N. Anderson, Trinity S. Robinson, Luke Strgar, Thomas L. Sutton, Patrick Conley, Christopher Klocke, Summer L. Gibbs, Young Hwan Chang, Guanming Wu, Melissa H. Wong, Alison H. Skalet
Summary: This study discovered a new population of tumor cells, called circulating hybrid cells, in the blood of uveal melanoma patients. The number of circulating hybrid cells at the time of initial treatment predicts the future development of disease spread. These cells have the potential to be used as a non-invasive and repeatable liquid biopsy for uveal melanoma patients.
Article
Virology
Alessandra Aiello, Flavia Giannessi, Zulema Antonia Percario, Katia Fecchi, Claudia Arenaccio, Stefano Leone, Maria Carollo, Elisabetta D'Aversa, Laurence Chaperot, Roberto Gambari, Massimo Sargiacomo, Elisabetta Affabris
Summary: This study investigated the effects of the Nef protein on intracellular signaling and extracellular vesicle release in uninfected pDCs. The results showed that Nef treatment induced phosphorylation of STAT-1 and STAT-2 and the production of various cytokines, chemokines, and growth factors. Additionally, Nef treatment slightly reduced the production of small vesicles and was associated with small vesicles.
Article
Pathology
Mona Phelippeau, Christine Lefebvre, Marie-Christine Jacob, Charlotte Syrykh, Julien Ghelfi, Sylvain Carras, Camille Laurent, Lysiane Molina, Severine Valmary-Degano
Summary: Follicular lymphoid hyperplasia induced by dasatinib is a recently described entity that is sometimes difficult to distinguish from small B-cell lymphoma. It is characterized by swollen lymph nodes with preserved follicular architecture, germinal centers with varied size and shape, a high number of mitoses, and tingible bodies macrophages. Follicular lymphoid hyperplasia can occur alone or in association with multiple reactive patterns. The immunohistochemical profile of germinal centers is CD20+, CD10+, BCL6+, BCL2-. Swollen lymph nodes disappear shortly after discontinuation of dasatinib. Clinicians and pathologists should be aware of this entity to avoid mistakenly suspecting lymphoma in patients with chronic myeloid leukemia treated with dasatinib. (c) 2022 Elsevier Masson SAS. All rights reserved.
ANNALES DE PATHOLOGIE
(2023)
Article
Oncology
Victor-Emmanuel Brett, Nicolas Lechevalier, Franck Trimoreau, Charles Dussiau, Sophie Dimicoli-Salazar, Lucie Coster, Isabelle Luquet, Nathalie Nadal, Benedicte Ribourtout, Elise Chapiro, Christine Lefebvre, Sylvie Tondeur, Estelle Balducci, Florence Nguyen-Khac, Claire Borie, Isabelle Radford-Weiss, Carole Barin, Virginie Eclache, Olivier Mansier, Audrey Bidet
Summary: In this study, a new entity called chromosomal abnormality with cytopenia of undetermined significance (CACtUS) was identified in some patients with cytopenias, absence of significant dysplasia, and presence of a chromosomal abnormality. Patients with CACtUS were found to have similar clinico-biological characteristics, overall survival, and risk of progression to high-risk MDS as low-risk MDS patients. Therefore, it is suggested that CACtUS patients be considered as high-risk CCUS and receive the follow-up regimen recommended for MDS patients.
GENES CHROMOSOMES & CANCER
(2023)
Article
Biochemistry & Molecular Biology
Dalil Hannani, Estelle Leplus, David Laurin, Benjamin Caulier, Caroline Aspord, Natacha Madelon, Ekaterina Bourova-Flin, Christian Brambilla, Elisabeth Brambilla, Anne-Claire Toffart, Karine Laulagnier, Laurence Chaperot, Joel Plumas
Summary: The purpose of ICI-based therapies is to help the patient's immune system combat tumors. Therapeutic vaccines with dendritic cells have not shown significant benefit, so a new vaccine based on an allogeneic dendritic cell line has been developed. This new vaccine demonstrates efficient activation of specific T cells and the synergistic effect of anti-PD-1 antibodies, showing potential for NSCLC patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Letter
Oncology
Florence Nguyen-Khac, Audrey Bidet, Marie-Berengere Troadec, Lauren Veronese, Nathalie Auger, Agnes Daudignon, Nathalie Nadal, Dominique Penther, Lucienne Michaux, Marina Lafage-Pochitaloff, Christine Lefebvre
Editorial Material
Hematology
Christine Lefebvre, Gautier Szymanski
Article
Immunology
Eleonora Sosa Cuevas, Benoit Roubinet, Stephane Mouret, Michel Thepaut, Florence de Fraipont, Julie Charles, Franck Fieschi, Ludovic Landemarre, Laurence Chaperot, Caroline Aspord
Summary: Subversion of immunity is a hallmark of cancer development. Tumor cells exploit dendritic cells' versatility to subvert their functions. The glycosylation patterns of melanoma tumor cells are associated with immune evasion, and targeting specific glycans can restore dendritic cells' functionality.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Lucile Dumolard, Caroline Aspord, Patrice N. Marche, Zuzana Macek Jilkova
Summary: In HBV infection, the interaction between the virus and the host immune system determines the development of the disease. Failure to mount a sufficient anti-viral immune response leads to chronic HBV infection. T cells and NK cells are crucial for viral clearance but are defective in chronic HBV infection. The dysregulation of immune checkpoints contributes to immune exhaustion and viral persistence. This review summarizes the expression and function of immune checkpoints in T and NK cells during HBV infection and discusses immunotherapeutic strategies targeting immune checkpoints in chronic HBV infection.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Olivier Manches, Khemary Um, Anne Boudier, Yasmina Maddouri, Sarah Lyon-Caen, Sam Bayat, Remy Slama, Claire Philippat, Valerie Siroux, Laurence Chaperot
Summary: The study explores the relationship between maternal and neonatal immune function, specifically focusing on cytokine secretion. It found that pregnant women and neonates have distinct cytokine secretion profiles. Several factors, including pre-conception BMI and smoking, were associated with cytokine levels in both mothers and children. This research provides insights into fetal immune development and the factors influencing maternal-child immune interactions.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, Research & Experimental
Solene Besson, Emilie Boucher, David Laurin, Olivier Manches, Caroline Aspord, Dalil Hannani, Pascal Fender
Summary: This study compared a protein-based virus-like particle (VLP) platform capable of displaying short epitopes or large tumor antigens, and evaluated their effectiveness against melanoma. The VLP displaying short epitopes completely inhibited tumor growth, while an improved platform displaying large antigens overcame immune allele restriction, broadening the immune response and paving the way for its potential use as an off-the-shelf vaccine in humans.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
(2023)
Review
Oncology
Eleonora Sosa Cuevas, Philippe Saas, Caroline Aspord
Summary: Immunotherapies using immune checkpoint blockers have shown clinical success in melanoma, but some patients still relapse or do not respond. Dendritic cells (DCs) play a key role in immune responses and their understanding is important for developing effective immunotherapies. This review provides an overview of DC diversity, their role in melanoma pathophysiology and clinical outcomes, tumor-induced DC subversion mechanisms, and DC-based therapeutic developments.
Article
Immunology
Camille Niveau, Eleonora Sosa Cuevas, Benoit Roubinet, Mylene Pezet, Michel Thepaut, Stephane Mouret, Julie Charles, Franck Fieschi, Ludovic Landemarre, Laurence Chaperot, Philippe Saas, Caroline Aspord
Summary: Dendritic cell subsets play a crucial role in shaping anti-tumour immunity. The study found that melanoma tumour cells display aberrant glycan motifs which can be sensed by dendritic cells through specific receptors. This interaction may lead to abnormal immune responses. The study suggests that targeting the glycan/receptor axis could be a promising strategy for improving cancer immunotherapy.
Article
Oncology
Jamila Kacher, Olivier Manches, Caroline Aspord, Herve Sartelet, Laurence Chaperot
Summary: In MYCN-nonamplified neuroblastoma, CCL2 produced by neuroblastoma cells induces the recruitment of antigen-presenting cells (DCs and monocytes/macrophages), allowing infiltration by T cells, in link with CCL19 and CCL22 production, hence favoring immune responses.
CANCER RESEARCH COMMUNICATIONS
(2022)